Loading...
13 ibuprofen COVID-19 controlled studies, 1 RCTs
-52% improvement
for early treatment, RR
1.52
[0.52-4.51]
https://c19early.org/ibmeta.html
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Rinott
-21%
1.21 [0.33-4.38]
death
3/87
9/316
Improvement, RR [CI]
Treatment
Control
Rinott
-12%
1.12 [0.37-3.34]
ventilation
4/87
13/316
Rinott
-40%
1.40 [0.51-3.81]
ICU
5/87
13/316
Abu Esba
-170%
2.70 [0.33-22.0]
death
1/40
11/357
Abu Esba
37%
0.63 [0.07-5.44]
death
40 (n)
357 (n)
Abu Esba
-45%
1.45 [0.44-4.81]
oxygen
40 (n)
357 (n)
Abu Esba
-18%
1.18 [0.59-2.36]
hosp.
40 (n)
357 (n)
Abu Esba
-85%
1.85 [0.42-8.13]
severe case
40 (n)
357 (n)
Sobhy (DB RCT)
52%
0.48 [0.24-0.95]
ICU
10/90
21/90
OT1
Sobhy (DB RCT)
52%
0.48 [0.24-0.95]
oxygen
10/90
21/90
OT1
Sobhy (DB RCT)
26%
0.74 [0.58-0.94]
hosp. time
90 (n)
90 (n)
OT1
Sobhy (DB RCT)
25%
0.75 [0.17-3.26]
no recov.
3/90
4/90
OT1
Sobhy (DB RCT)
43%
0.57 [0.25-1.29]
no recov.
8/90
14/90
OT1
Sobhy (DB RCT)
48%
0.52 [0.28-0.95]
no recov.
13/90
25/90
OT1
Sobhy (DB RCT)
41%
0.59 [0.37-0.94]
no recov.
20/90
34/90
OT1
Choi (PSM)
-240%
3.40 [0.64-18.1]
progression
case control
Samimagham
-100%
2.00 [1.33-3.02]
death
63 (n)
95 (n)
Samimagham
-428%
5.28 [1.82-15.3]
severe case
14/63
4/95
Samimagham
-13%
1.13 [1.02-1.25]
progression
60/63
80/95
Kragholm
4%
0.96 [0.72-1.23]
progression
264 (n)
3,738 (n)
Wong
-23%
1.23 [0.90-1.68]
death
population-based cohort
Wong
17%
0.83 [0.56-1.25]
death
population-based cohort
Reese (PSM)
9%
0.91 [0.62-1.35]
death
5,737 (n)
5,737 (n)
Reese (PSM)
-303%
4.03 [3.69-4.40]
severe case
5,737 (n)
5,737 (n)
Drake
10%
0.90 [0.71-1.13]
death
n/a
n/a
Leal
3%
0.97 [0.94-1.00]
cases
n/a
n/a
Campbell (PSW)
0%
1.00 [0.99-1.01]
death
1,814 (n)
20,311 (n)
Campbell (PSW)
1%
0.99 [0.98-1.00]
death
1,814 (n)
20,311 (n)
Xie
-12%
1.12 [0.92-1.38]
hosp.
population-based cohort
OT1
Xie
-8%
1.08 [0.95-1.22]
cases
population-based cohort
OT1
Loucera
48%
0.52 [0.34-0.78]
death
519 (n)
15,449 (n)
Ibuprofen COVID-19 outcomes
c19 early .org
October 2023
1 OT: comparison with other treatment
Favors ibuprofen
Favors control
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit